BMJ  2005;331:810 (8 October), doi:10.1136/bmj.38569.471007.AE (published 12 September 2005)

Paper

Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data

¹ Cochrane Renal Group, Centre for Kidney Research, Children's Hospital at Westmead, Westmead, NSW 2145, Australia, ² Centre for Transplant and Renal Research, Department of Renal Medicine, Westmead Hospital, Westmead, ³ School of Public Health, University of Sydney, Sydney, NSW 2006, Australia, ⁴ Department of Public Health and Epidemiology, University of Birmingham, Birmingham B15 2TT

Objective To compare the positive and negative effects of tacrolimus and ciclosporin as initial treatment for renal transplant recipients.

Design Systematic review.

Data sources and study selection Reports of comparative randomised trials of tacrolimus and ciclosporin identified by searches of Medline, Embase, the Cochrane Register of Controlled Trials, the Cochrane Renal Group Specialist Register, and conference proceedings.

Data extraction and synthesis Two reviewers assessed trials for eligibility and quality and extracted data independently. Data were synthesised (random effects model) and results expressed as relative risk (RR), with values < 1 favouring tacrolimus. Subgroup analysis and meta-regression were used to examine potential effect modification by differences in trial design and immunosuppressive co-interventions.

Results 123 reports from 30 trials (4102 patients) were included. At six months, graft loss was significantly reduced in tacrolimus treated recipients (RR = 0.56, 95% confidence interval 0.36 to 0.86), and this effect persisted up to three years. The relative reduction in graft loss with tacrolimus diminished with higher concentrations of tacrolimus (P = 0.04) but did not vary with ciclosporin formulation (P = 0.97) or ciclosporin concentration (P = 0.38). At one year, tacrolimus treated patients had less acute rejection (RR = 0.69, 0.60 to 0.79) and less steroid resistant rejection (RR = 0.49, 0.37 to 0.64) but more diabetes mellitus requiring insulin (RR = 1.86, 1.11 to 3.09), tremor, headache, diarrhoea, dyspepsia, and vomiting. The relative excess of diabetes increased with higher concentrations of tacrolimus (P = 0.003). Ciclosporin treated recipients had significantly more constipation and cosmetic side effects. No differences were seen in infection or malignancy.

Conclusions Treating 100 recipients with tacrolimus instead of ciclosporin for the first year after transplantation avoids 12 patients having acute rejection and two losing their graft but causes an extra five patients to develop insulin dependent diabetes. Optimal drug choice may vary between patients.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Uncertainty in heterogeneity estimates in meta-analyses

John P A Ioannidis, Nikolaos A Patsopoulos, and Evangelos Evangelou
BMJ 2007 335: 914-916. [Extract] [Full Text] [PDF]

Optimal therapy after kidney transplantation varies
BMJ 2005 331: 0. [Full Text]

Measuring inconsistency in meta-analyses

Julian P T Higgins, Simon G Thompson, Jonathan J Deeks, and Douglas G Altman
BMJ 2003 327: 557-560. [Extract] [Full Text] [PDF]

Balancing benefits and harms in health care

Luis Gabriel Cuervo and Mike Clarke
BMJ 2003 327: 65-66. [Extract] [Full Text] [PDF]

Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials

Greg A Knoll and Robert C Bell
BMJ 1999 318: 1104-1107. [Abstract] [Full Text] [PDF]

Bias in meta-analysis detected by a simple, graphical test

Matthias Egger, George Davey Smith, Martin Schneider, and Christoph Minder
BMJ 1997 315: 629-634. [Abstract] [Full Text]

Related external webpages:

NHS Health Technology Assessment Programme

This article has been cited by other articles:

• Kramer, B. K., Del Castillo, D., Margreiter, R., Sperschneider, H., Olbricht, C. J., Ortuno, J., Sester, U., Kunzendorf, U., Dietl, K.-H., Bonomini, V., Rigotti, P., Ronco, C., Tabernero, J. M., Rivero, M., Banas, B., Muhlbacher, F., Arias, M., Montagnino, G., for the European Tacrolimus versus Ciclosporin Mic, (2008). Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results. Nephrol Dial Transplant 23: 2386-2392 [Abstract] [Full text]  
• Mrkobrada, M., Thiessen-Philbrook, H., Haynes, R. B., Iansavichus, A. V., Rehman, F., Garg, A. X. (2008). Need for Quality Improvement in Renal Systematic Reviews. CJASN 3: 1102-1114 [Abstract] [Full text]  
• Chadban, S. (2008). New-onset diabetes after transplantation--should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients. Nephrol Dial Transplant 23: 1816-1818 [Full text]  
• Shirali, A. C., Bia, M. J. (2008). Management of Cardiovascular Disease in Renal Transplant Recipients. CJASN 3: 491-504 [Abstract] [Full text]  
• Gelens, M. A. C. J., Christiaans, M. H. L., van Hooff, J. P. (2008). Glucose metabolism before and after conversion from cyclosporine microemulsion to tacrolimus in stable renal recipients. Nephrol Dial Transplant 23: 701-706 [Abstract] [Full text]  
• Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vitko, S., Nashan, B., Gurkan, A., Margreiter, R., Hugo, C., Grinyo, J. M., Frei, U., Vanrenterghem, Y., Daloze, P., Halloran, P. F., the ELITE-Symphony Study, (2007). Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation. NEJM 357: 2562-2575 [Abstract] [Full text]  
• Walker, M. R., Lovel, S. F., Melrose, C. A. (2007). Orthodontic treatment of a patient with a renal transplant and drug-induced gingival overgrowth: a case report. J. Orthod. 34: 220-228 [Abstract] [Full text]  
• Ioannidis, J. P A, Patsopoulos, N. A, Evangelou, E. (2007). Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335: 914-916 [Full text]  
• Borrows, R., Chusney, G., Loucaidou, M., James, A., Goel, S., Borrows, S., Van Tromp, J., Cairns, T., Griffith, M., Hakim, N., McLean, A., Palmer, A., Papalois, V., Taube, D. (2007). Analysis of Factors Influencing Tacrolimus Levels and Immunoassay Bias in Renal Transplantation. J Clin Pharmacol 47: 1035-1042 [Full text]  
• Schiff, J., Cole, E., Cantarovich, M. (2007). Therapeutic Monitoring of Calcineurin Inhibitors for the Nephrologist. CJASN 2: 374-384 [Abstract] [Full text]  
• Rodrigo, E., Fernandez-Fresnedo, G., Valero, R., Ruiz, J. C., Pinera, C., Palomar, R., Gonzalez-Cotorruelo, J., Gomez-Alamillo, C., Arias, M. (2006). New-Onset Diabetes after Kidney Transplantation: Risk Factors. J. Am. Soc. Nephrol. 17: S291-S295 [Abstract] [Full text]  
• Goldfarb-Rumyantzev, A. S., Smith, L., Shihab, F. S., Baird, B. C., Habib, A. N., Lin, S.-j., Barenbaum, L. L. (2006). Role of Maintenance Immunosuppressive Regimen in Kidney Transplant Outcome. CJASN 1: 563-574 [Abstract] [Full text]  

Rapid Responses:

Read all Rapid Responses

Is tacrolimus superior to ciclosporin after renal transplantation?

Karsten Midtvedt, et al.
bmj.com, 23 Sep 2005 [Full text]

Case for tacrolimus as primary immunosuppression for renal transplant recipients

Badri M Shrestha MS MPhil FRCS
bmj.com, 9 Oct 2005 [Full text]